Development and impact of prescription opioid abuse deterrent formulation technologies

Drug and Alcohol Dependence

Volumn 138, Issue 1, 2014, Pages 1-6

  Alexander, Louis ^a   Mannion, Richard O ^a   Weingarten, Brianne ^a   Fanelli, Richard J ^a   Stiles, Gary L ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

Abuse deterrent formulation; Non medical use; Opioid analgesic; Pain relief; Unintended misuse

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; DETERX; MORPHINE SULFATE PLUS NALTREXONE; NKTR 181; OPIATE; OXYCODONE; OXYMORPHONE; TAPENTADOL; TARGINIQ; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

DRUG ABUSE; DRUG FORMULATION; DRUG MISUSE; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PEER REVIEW; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; DRUG LABELING; MEDICINAL CHEMISTRY; OPIOID-RELATED DISORDERS; PROCEDURES; UNITED STATES;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DRUG LABELING; HUMANS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84897486610     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.02.006     Document Type: Review

References (64)

1. Albert S., Brason F.W., Sanford C.K., Dasgupta N., Graham J., Lovette B. Project Lazarus community-based overdose prevention in rural North Carolina. Pain Med. 2011, 12(Suppl. 2):S77-S85.
2. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
3. Barry D.T., Savant J.D., Beitel M., Cutter C.J., Moore B.A., Schottenfeld R.S., Fiellin D.A. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am. J. Addict. 2013, 22:212-217.
4. Bartholomäus J., Arkenau-Maric E., Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin. Drug Deliv. 2012, 9:879-891.
5. Butler S.F., Benoit C., Budman S.H., Fernandez K.C., McCormick C., Venuti S.W., Katz N. Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct. J. 2006, 2:5.
6. Butler S.F., Black R.A., Grimes Serrano J.M., Wood M.E., Budman S.H. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns and functional severity. J. Opioid Manag. 2010, 6:239-252.
7. Butler S.F., Black R., Grimes Serrano J.M., Folensbee L., Chang A., Katz N. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010, 11:81-91.
8. Butler S.F., Black R.A., Cassidy T.A., Dailey T.M., Budman S.H. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct. J. 2011, 19:29-45.
9. Butler S.F., Cassidy T.A., Chilcoat H., Black R.A., Landau C., Budman S.H., Coplan P.M. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J. Pain 2013, 14:351-358.
10. Cassidy T.A., Dasmahapatra P., Black R.A., Wieman M.S., Butler S.F. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2013, (Epub ahead of print).
11. Centers for Disease Control and Prevention Unintentional poisoning deaths - United States, 1999-2004. MMWR 2007, 56:93-96.
12. Centers for Disease Control and Prevention Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR 2012, 61:101-105.
13. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. N. Engl. J. Med. 2012, 367:187-189.
14. Collelgium Pharmaceutical Tamper-resistant, extended-release products for the treatment of chronic pain 2011, Available from http://www.collegiumpharma.com/ (accessed 06.05.13).
15. Comer S.D., Sullivan M.A., Vosburg S.K., Manubay J., Amass L., Cooper Z.D., Saccone P., Kleber H.D. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010, 105:709-718.
16. Committee on Advancing Pain Research, Care, and Education, Board on Health Sciences Policy, Institute of Medicine of the National Academies Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research 2011, The National Academies Press, Washington, DC, (accessed 04.05.13). http://www.nap.edu/catalog.php%3Frecord_id=13172.
17. Cone E.J., Giordano J., Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013, 131:100-105.
18. Coplan P., Chilcoat H., Baumgartner T., Landau C. Design of post-marketing study program to assess the effects of a reformulated extended-release oxycodone tablet on its abuse. Pharmacoepidemiol. Drug Saf. 2012, 21(Suppl. s3):446. (abstract #963).
19. Coplan P., Kale H., Sandstrom L., Chilcoat H. Changes after reformulation of extended-release oxycodone in calls to U.S. Poison Centers for oxycodone and heroin. Pharmacoepidemiol. Drug Saf. 2012, 21(Suppl. s3):241. (abstract #513).
20. Coplan P.M., Green C., Perrin N., Campbell C., Severtson G., Bucher-Bartelson B., Chilcoat H., Sessler N.E., Kale H. Poster Session Presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2013, (poster #250).
21. Coplan P.M., Kale H., Sandstrom L., Landau C., Chilcoat H.D. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol. Drug Saf. 2013, 22:1274-1282.
22. Cupp M. New OxyContin (oxycodone controlled-release) formulation. Pharmacist's Lett. 2010, 26(261201):67.
23. Drugs.com (Internet). Nucynta Information from Drugs.com; c2000-10. Available from: (updated: 16.04.10; cited: 20.12.13). http://www.drugs.com/pro/nucynta.html.
24. Duggan S.T., Scott L.J. Morphine/naltrexone. CNS Drugs 2010, 24:527-538.
25. Embeda (morphine sulfate and naltrexone HCl) Extended Release Capsules (package insert) 2010, King Pharmaceuticals, Inc., Bristol, TN, Available from http://labeling.pfizer.com/ShowLabeling.aspx?id=694 (accessed 06.05.13).
26. Engel K., Reuter J., Seiler C., Schulte Monting J., Jakob T., Schempp C.M. Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. J. Eur. Acad. Dermatol. Venereol. 2008, 22:447-450.
27. Food and Drug and Administration News and Events. FDA Approves New Formulation for OxyContin 2010, Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm (accessed 05.05.13).
28. Food and Drug and Administration FDA Adverse Event Reporting System (FAERS) (formerly AERS) 2012, Available from http://www.fda.gov/cder/aers/default.htm (accessed 06.05.13).
29. Food and Drug and Administration Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioids 2012, http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm (accessed 06.05.13).
30. Food and Drug and Administration Draft Guidance for Industry: Abuse-Deterrent Opioids - Evaluation and Labeling 2013, Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidlines/UCM334743.htm (accessed 02.05.13).
31. Food and Drug and Administration FDA News Release: FDA Approves abuse-deterrent labeling for reformulated OxyContin 2013, Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM348252.htm (accessed 05.05.13).
32. Food and Drug Administration FDA Statement: Original Opana ER Relisting Determination 2013, (accessed 20.12.13). http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm.
33. Gibbons R.D., Amatya A.K., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., Mann J.J. Post-approval drug safety surveillance. Annu. Rev. Public Health 2010, 31:419-437.
34. Harris S.C., Perrino P.J., Smith I., Shram M.J., Colucci S.V., Bartlett C., Sellers E.M. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J. Clin. Pharmacol. 2013, (Epub ahead of print).
35. Havens J.R., Oser C.B., Leukefeld C.G. Increasing prevalence of prescription opiate misuse over time among rural probationers. J. Opioid Manag. 2007, 3:107-111.
36. Helm S., Trescot A., Colson J., Sehgal N., Silverman S. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician 2008, 11:225-235.
37. Jones C.M., Mack K.A., Paulozzi L.J. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013, 309:657-659.
38. Katz N., Fernandez K., Chang A., Benoit C., Butler S.F. Internet-based survey of nonmedical prescription opioid use in the United States. Clin. J. Pain 2008, 24:528-535.
39. Katz N., Dart R.C., Bailey E., Trudeau J., Osgood E., Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am. J. Drug Alcohol Abuse 2011, 37:205-217.
40. Merrigan T., Friedmann N., Butera P., Klutzaritz V., Gilmore D., Webster L. Abuse-resistant, controlled-release oxycodone treats chronic pain. Presented at American Academy of Pain Medicine 24th Annual Meeting 2008.
41. Moorman-Li R., Motycka C.A., Inge L.D., Congdon J.M., Hobson S., Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P & T 2012, 37:412-418.
42. National Drug Intelligence Center OxyContin diversion and abuse 2001, (accessed 06.05.13). http://www.justice.gov/archive/ndic/pubs/651/abuse.htm.
43. Nektar Therapeutics Product Fact Sheet: CNS/PaIN-NKTR-181: new mu-opioid analgesic with novel molecular structure in clinical development as a safer, abuse-deterrent pain therapeutic 2011, (accessed 06.05.13). http://www.nektar.com/pdf/pipeline/NKTR-181/product_fact_sheet.pdf.
44. Nektar Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, A First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2013, (accessed 20.12.13). http://ir.nektar.com/releasedetail.cfm%3FReleaseID=772395.
45. Office of National Drug Control Policy Epidemic: Responding To America's Prescription Drug Abuse Crisis 2011, https://www.ncjrs.gov/pdffiles1/ondcp/rx_abuse_plan.pdf.
46. Okie S. A flood of opioids, a rising tide of deaths. N. Engl. J. Med. 2010, 363:1981-1983.
47. Opana ER (Oxymorphone HCl) Extended-Release Tablets (package insert) 2011, Endo Pharmaceuticals, Chadds Ford, PA, Available at: www.endo.com/pdf/products/Opana%20ER%20 PI%2020111212.pdf (accessed 03.02.12).
48. Oxecta (oxycodone HCl, USP) Tablets (package insert) 2011, King Pharmaceuticals, Inc., Bristol, TN, (accessed 06.05.13). http://labeling.pfizer.com/ShowLabeling.aspx%3Fid=620.
49. Passik S.D., Hays L., Eisner N., Kirsh K.L. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J. Pain Palliat Care Pharmacother. 2006, 20:5-13.
50. Paulozzi L.J., Kilbourne E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011, 12:747-754.
51. Raffa R.B., Pergolizzi J.V. Opioid formulations designed to resist/deter abuse. Drugs 2010, 70:1657-1675.
52. Reifler L.M., Droz D., Bailey J.E., Schnoll S.H., Fant R., Dart R.C., Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain Med. 2012, 13:434-442.
53. Rice B., Kirson N.Y., Shei A., Cummings A.K., Bodnar K., Birnbaum H.G., Ben-Joseph R. Hidden costs to employers of opioid abuse - healthcare costs, work-loss costs, and prevalence of opioid abuse among commercially-insured beneficiaries. Poster Session Presented at PAINWeek 2013 2013, (poster #95).
54. Rodriguez E.M., Staffa A., Graham D. The role of databases in drug post-marketing surveillance. Pharmacoepidemiol. Drug Saf. 2001, 10:407-410.
55. Romach M.K., Schoedel K.A., Seller E.M. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013, 130:13-23.
56. Rosenblum A., Marsch L.A., Joseph H., Portenoy R.K. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp. Clin. Psychopharmacol. 2008, 16:405-416.
57. Rossiter L.F., Rice B., Kirson N.Y., Shei A., Kaminsky M., Birnbaum H.G., Holly P., Ben-Joseph R. The impact of an abuse-deterrent formulation of an extended-release opioid on healthcare utilization and costs. Poster Session Presented at PAINWeek 2013 2013, (poster #94).
58. Severtson S.G., Bartelson B.B., Davis J., Munoz A., Schneider M.F., Coplan P., Chilcoat H., Green J.L., Dart R.C. Decline in rates of abuse of extended release (ER) oxycodone following the introduction of a reformulated ER oxycodone product using data from the RADARS System Poison Center Program (Abstract PF088). International Association for the Study of Pain. 14th Annual World Congress on Pain 2012, Abstract retrieved from IASP Abstract database at http://www.abstracts2view.com/iasp/sessionindex.php.
59. Suboxone (buprenorphine and naloxone) Sublingual Tablets (package insert) 2011, Reckitt Benckiser, Richmond, VA, www.suboxone.com/pdfs/SuboxonePI_tablet.pdf (accessed 06.05.13).
60. Substance Abuse and Mental Health Services Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD. 2011.
61. Vosburg S.K., Jones J.D., Manubay J.M., Ashworth J.B., Benedek I.H., Comer S.D. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012, 126:206-215.
62. ® (non-TRF) in prescription opioid abusers. Addiction 2013, 108:1095-1106.
63. Walley A.Y., Xuam Z., Hackman H.H., Quinn E., Doe-Simkins M., Sorensen-Alawad A., Ruiz S., Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174.
64. Warner M., Chen L.H., Makuc D.M. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 2009, 22:1-8.